OUP user menu

Expression of GLUT1 in Primary Renal Tumors
Morphologic and Biologic Implications

Ayhan Ozcan MD, Steven S. Shen MD, PhD, Qihui “Jim” Zhai MD, Luan D. Truong MD
DOI: http://dx.doi.org/10.1309/HV6NJVRQKK4QHM9F 245-254 First published online: 1 August 2007


This study aimed to assess whether glucose transporter 1 (GLUT1) is useful in prognostication or differential diagnosis of renal tumors. GLUT1 immunostain for 228 renal tumors showed a membranous or cytoplasmic pattern. The membranous pattern was seen in 86.2% of 145 clear cell renal cell carcinomas (RCCs) and 100% of 11 transitional cell carcinomas (TCCs) but in no oncocytomas, other subtypes of RCC, or sarcomatoid areas of RCCs. The cytoplasmic pattern was seen in 55.2% of 145 clear cell RCCs, 38% of papillary RCCs (11/29), 13% of chromophobe RCCs (2/16), 22% of oncocytomas (5/23), and 82% of TCCs (9/11). Western blot showed a markedly increased GLUT1 protein content in clear cell RCCs compared with a low level in papillary RCCs and normal kidney specimens. GLUT1 expression in clear cell RCC was not significantly correlated with patient survival, tumor grade, or tumor stage. GLUT1 may be a novel target for immunotherapy and a useful marker in the differential diagnosis and classification of renal tumors.

Key Words:
  • GLUT1
  • Renal neoplasm
  • Transitional cell carcinoma
  • Tissue microarray
  • Immunohistochemistry
  • Western blot